Special scan could guide stronger radiation to tough tumors
NCT ID NCT04846309
First seen Jun 07, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This early-stage trial tests whether a special PET scan (FMISO) can identify oxygen-starved (hypoxic) areas in esophageal tumors. Patients with hypoxic tumors receive a higher radiation dose, while others get standard care. The goal is to see if this personalized approach is safe and might improve treatment outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FMISO PET scan and MRI-guided radiation therapy
What this could lead to
If successful, this approach could personalize radiation doses for esophageal cancer, potentially improving tumor control without increasing side effects.
What could go wrong
This is a very early (Phase 1) safety trial with only 16 participants. The higher radiation dose may cause more side effects, and the imaging technique may not reliably identify hypoxic tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.